Nasal immunization of mice with Lactobacillus casei expressing the Pneumococcal Surface Protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge

Microbes and Infection

Volumn 10, Issue 5, 2008, Pages 481-488

  Campos, Ivana B ^a,b   Darrieux, Michelle ^a,b   Ferreira, Daniela M ^a,b   Miyaji, Eliane N ^a,b   Silva, Débora A ^a,b   Arêas, Ana Paula M ^a,b   Aires, Karina A ^a,b   Leite, Luciana C C ^a,b   Ho, Paulo L ^a,b   Oliveira, Maria Leonor S ^a,b  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Lactic acid bacteria; PspA; Streptococcus pneumoniae

Indexed keywords

MEMBRANE PROTEIN; PNEUMOCOCCAL SURFACE PROTEIN A; STREPTOCOCCUS VACCINE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; C57BL 6 MOUSE; CLADISTICS; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DISEASE MODEL; FEMALE; LACTOBACILLUS CASEI; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; SURVIVAL TIME;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; COMPLEMENT ACTIVATION; FEMALE; GENETIC VECTORS; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN G; LACTOBACILLUS CASEI; MICE; MICE, INBRED C57BL; PLASMIDS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; TRANSFORMATION, BACTERIAL;

ANIMALIA; LACTOBACILLUS CASEI; MUS; STREPTOCOCCUS PNEUMONIAE;

EID: 43649105546     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2008.01.007     Document Type: Article

References (31)

1. Pneumococcal vaccines. WHO position paper, Wkly Epidemiol. Rec. 74 (1999) 177-183
2. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348 (2003) 1737-1746
3. Reinert R.R. Pneumococcal conjugate vaccines-a European perspective. Int. J. Med. Microbiol. 294 (2004) 277-294
4. Tai S.S. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit. Rev. Microbiol. 32 (2006) 139-153
5. Tu A.H., Fulgham R.L., McCrory M.A., Briles D.E., and Szalai A.J. Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect. Immun. 67 (1999) 4720-4724
6. Shaper M., Hollingshead S.K., Benjamin W.H., and Briles D.E. PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin. Infect. Immun. 72 (2004) 5031-5040
7. Jedrzejas M.J. Unveiling molecular mechanisms of pneumococcal surface protein A interactions with antibodies and lactoferrin. Clin. Chim. Acta 367 (2006) 1-10
8. Hollingshead S.K., Becker R., and Briles D.E. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect. Immun. 68 (2000) 5889-5900
9. McDaniel L.S., Ralph B.A., McDaniel D.O., and Briles D.E. Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb. Pathog. 17 (1994) 323-337
10. Detmer A., and Glenting J. Live bacterial vaccines - a review and identification of potential hazards. Microb. Cell Fact. 5 (2006) 23-34
11. Oliveira M.L., Arêas A.P., Campos I.B., Monedero V., Perez-Martinez G., Miyaji E.N., Leite L.C., Aires K.A., and Lee Ho P. Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes Infect. 8 (2006) 1016-1024
12. Gilbert C., Robinson K., Le Page R.W., and Wells J.M. Heterologous expression of an immunogenic pneumococcal type 3 capsular polysaccharide in Lactococcus lactis. Infect. Immun. 68 (2000) 3251-3260
13. Audouy S.A., van Selm S., van Roosmalen M.L., Post E., Kanninga R., Neef J., Estevao S., Nieuwenhuis E.E., Adrian P.V., Leenhouts K., and Hermans P.W. Development of lactococcal GEM-based pneumococcal vaccines. Vaccine 25 (2007) 2497-2506
14. Hanniffy S.B., Carter A.T., Hitchin E., and Wells J.M. Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J. Infect. Dis. 195 (2007) 185-193
15. Miyaji E.N., Ferreira D.M., Lopes A.P., Brandileone M.C., Dias W.O., and Leite L.C.C. Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades. Infect. Immun. 70 (2002) 5086-5090
16. Wu H.Y., Nahm M.H., Guo Y., Russell M.W., and Briles D.E. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J. Infect. Dis. 175 (1997) 839-846
17. Waterfield N.R., Le Page R.W., Wilson P.W., and Wells J.M. The isolation of lactococcal promoters and their use in investigating bacterial luciferase synthesis in Lactococcus lactis. Gene 165 (1995) 9-15
18. Ghaffar F., Barton T., Lozano J., Muniz L.S., Hicks P., Gan V., et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin. Infect. Dis. 39 (2004) 930-938
19. Millar E.V., O'Brien K.L., Watt J.P., Bronsdon M.A., Dallas J., Whitney C.G., et al. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin. Infect. Dis. 43 (2006) 8-15
20. Arulanandam B.P., Lynch J.M., Briles D.E., Hollingshead S., and Metzger D.W. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect. Immun. 69 (2001) 6718-6724
21. Yamamoto M., McDaniel L.S., Kawabata K., Briles D.E., Jackson R.J., McGhee J.R., et al. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection. Infect. Immun. 65 (1997) 640-644
22. Yamamoto M., Briles D.E., Yamamoto S., Ohmura M., Kiyono H., and McGhee J.R. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J. Immunol. 161 (1998) 4115-4121
23. Briles D.E., Hollingshead S., Brooks-Walter A., Nabors G.S., Ferguson L., Schilling M., et al. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 18 (2000) 1707-1711
24. Briles D.E., Hollingshead S.K., King J., Swift A., Braun P.A., Park M.K., et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J. Infect. Dis. 182 (2000) 1694-1701
25. Nabors G.S., Braun P.A., Herrmann D.J., Heise M.L., Pyle D.J., Gravenstein S., et al. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 18 (2000) 1743-1754
26. Hollingshead S.K., Baril L., Ferro S., King J., Coan P., and Briles D.E. Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries. J. Med. Microbiol. 55 (2006) 215-221
27. Pimenta F.C., Ribeiro-Dias F., Brandileone M.C., Miyaji E.N., Leite L.C., and Sgambatti de Andrade A.L. Genetic diversity of PspA types among nasopharyngeal isolates collected during an ongoing surveillance study of children in Brazil. J. Clin. Microbiol. 44 (2006) 2838-2843
28. Paterson G.K., and Mitchell T.J. Innate immunity and the pneumococcus. Microbiology 152 (2006) 285-293
29. Ren B., Szalai A.J., Hollingshead S.K., and Briles D.E. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect. Immun. 72 (2004) 114-122
30. Ferreira D.M., Miyaji E.N., Oliveira M.L., Darrieux M., Areas A.P., Ho P.L., and Leite L.C. DNA vaccines expressing pneumococcal surface protein A (PspA) elicit protection levels comparable to recombinant protein. J. Med. Microbiol. 55 (2006) 375-378
31. Cortes-Perez N.G., Lefevre F., Corthier G., Adel-Patient K., Langella P., and Bermudéz-Humarán L.G. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria. Vaccine 25 (2007) 6581-6588